Düsseldorf Startup Pioneering New Treatment for Fatty liver Disease
Table of Contents
- 1. Düsseldorf Startup Pioneering New Treatment for Fatty liver Disease
- 2. Understanding the Shift: from NAFLD to MASLD
- 3. The Prevalence and Risks of MASLD
- 4. CureDiab’s Innovative Approach: Targeting GABAA Receptors
- 5. Current Treatments and Their Limitations
- 6. From Diabetes Research to Liver Disease Innovation
- 7. Looking Ahead: A Potential Exit Strategy
- 8. How do the sulfur compounds developed by CureDiab improve liver function in patients with NAFLD and NASH?
- 9. CureDiab: A Novel Approach to Fatty Liver Disease with Sulfur Compounds
- 10. Understanding the Link Between Sulfur Metabolism and Liver Health
- 11. how CureDiab’s Sulfur Compounds Work
- 12. Clinical Trial Data and Early Results
- 13. The Growing Prevalence of Fatty Liver Disease
- 14. Beyond Treatment: Preventative strategies & Lifestyle Modifications
- 15. The Future of Liver Health: CureDiab’s Vision
Düsseldorf, Germany – February 13, 2026 – A newly established biotechnology firm, CureDiab, is making important strides in the growth of a novel treatment for metabolic dysfunction-associated steatotic liver disease (MASLD), a condition increasingly linked to diabetes and other metabolic disorders. The company’s research focuses on thioacrylamide derivatives with the potential to address the root causes of this widespread ailment, offering hope for a condition affecting millions globally.
Understanding the Shift: from NAFLD to MASLD
Historically known as non-alcoholic fatty liver disease (NAFLD), the condition was recently renamed MASLD in 2023 to accurately reflect its strong connection to metabolic risk factors. These factors include obesity, insulin resistance, prediabetes, type 2 diabetes, high blood lipid levels, and arterial hypertension, all of which play a crucial role in the development and progression of the disease. Recent data from the Centers for Disease Control and Prevention estimates that around 40% of American adults now have NAFLD, highlighting the growing public health concern.
The Prevalence and Risks of MASLD
According to CureDiab Managing Director Jürgen Eckel, MASLD is the most common chronic liver disease worldwide, impacting approximately 30 percent of the adult population, a figure that continues to rise. Approximately two-thirds of individuals with type 2 diabetes are also affected. The disease progresses from simple fat accumulation in the liver, known as steatosis, to potentially inflammatory stages like MASH (metabolic dysfunction-associated steatohepatitis). If left unchecked, MASH can lead to irreversible liver fibrosis, and ultimately, cirrhosis, often requiring a liver transplant.
CureDiab’s Innovative Approach: Targeting GABAA Receptors
CureDiab’s approach differs from existing therapies. The company is exploring thioacrylamide compounds, like HK3 and HK4, which interact with GABAA receptors in the liver. These compounds act as positive allosteric modulators, amplifying the receptors’ natural effects to regulate fat metabolism, reduce inflammation, and improve insulin resistance. Initial cell experiments demonstrate the potential for these compounds to protect liver cells from damage caused by lipid buildup.
Furthermore, HK3 has demonstrated the ability to reduce fibrotic signals from stellate cells within the liver, potentially slowing or halting disease progression. This dual action sets it apart from current treatment options.
Current Treatments and Their Limitations
Currently, the primary treatment for MASLD remains lifestyle intervention, specifically weight reduction of around ten percent, which can mitigate steatosis, inflammation, and fibrosis. While medications like GLP-1 receptor agonists and resmetirom show promise, their effectiveness is primarily seen in advanced stages of the disease and benefits only a subset of patients—estimated at 25 to 30 percent in the case of resmetirom.
| Treatment | mechanism | Efficacy | Limitations |
|---|---|---|---|
| Lifestyle Intervention | Weight Loss, Dietary Changes, Exercise | Significant improvement in steatosis, inflammation & fibrosis | Requires strict adherence; not always enduring. |
| GLP-1 Receptor Agonists | Improves Insulin Sensitivity & Fat Metabolism | Positive effects on liver fat and inflammation | Primarily effective in advanced stages. |
| Resmetirom | Targets thyroid hormone receptor-beta | Remission or improvement in liver condition for a subset of patients | Limited efficacy (25-30% benefit) and potential side effects. |
| CureDiab’s HK3 | Modulates GABAA receptors; reduces fibrosis | Promising pre-clinical results; cell protection and anti-fibrotic effects. | Currently in pre-clinical testing; human trials pending. |
From Diabetes Research to Liver Disease Innovation
The genesis of CureDiab stems from the research of founder Jürgen Eckel, who initially aimed to develop therapies for diabetes. Recognizing a strong link between the two conditions, Eckel and his team shifted their focus to MASLD, establishing CureDiab as a spin-off from the german Diabetes Center (DDZ) in Düsseldorf in 2021. the company received initial funding of 400,000 euros, followed by additional investment including support from NRW Bank.
Looking Ahead: A Potential Exit Strategy
curediab is not aspiring to become a large pharmaceutical company. Rather, Eckel envisions an “exit,” or acquisition by an established pharmaceutical firm, once the effectiveness of their compounds is definitively proven. They are also exploring the potential of HK3 in treating fibrosis in other organs, expanding the potential therapeutic applications of their research.
What role do you think lifestyle interventions will continue to play alongside pharmaceutical advancements in treating MASLD? And how significant is early detection in combating the progression of this increasingly prevalent disease?
Disclaimer: The information provided in this article is for general knowledge and informational purposes only, and does not constitute medical advice. it is indeed essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
How do the sulfur compounds developed by CureDiab improve liver function in patients with NAFLD and NASH?
CureDiab: A Novel Approach to Fatty Liver Disease with Sulfur Compounds
Düsseldorf-based start-up CureDiab is making waves in the medical community with its innovative approach to tackling Non-Alcoholic Fatty Liver Disease (NAFLD) and its more severe form, Non-Alcoholic Steatohepatitis (NASH). Unlike many current treatments focusing on symptom management,CureDiab is directly addressing the metabolic dysfunction at the heart of these conditions using specifically formulated sulfur compounds.
Understanding the Link Between Sulfur Metabolism and Liver Health
For years, the role of sulfur metabolism in liver health has been underestimated. Sulfur, an essential mineral, is crucial for numerous biological processes, including detoxification, antioxidant defence, and the synthesis of glutathione – a master antioxidant. In individuals with NAFLD/NASH, sulfur metabolism is frequently enough impaired, leading to:
* Increased oxidative stress: Damaging liver cells and promoting inflammation.
* Reduced glutathione levels: Diminishing the liver’s ability to neutralize harmful toxins.
* Impaired bile acid metabolism: Contributing to fat accumulation in the liver.
CureDiab’s research, stemming from collaborations with the University of Düsseldorf’s metabolic research department, suggests that restoring optimal sulfur metabolism can considerably improve liver function and reverse the progression of fatty liver disease.
how CureDiab’s Sulfur Compounds Work
CureDiab isn’t simply advocating for increased sulfur intake through diet. Their proprietary formulations utilize specific bioavailable sulfur compounds designed to bypass metabolic bottlenecks and directly support liver function. These compounds work on multiple fronts:
- Boosting Glutathione Production: The core of CureDiab’s approach is enhancing the liver’s natural production of glutathione.This strengthens the liver’s defense against oxidative stress and toxins.
- Improving bile Acid Metabolism: certain sulfur compounds aid in the efficient processing and excretion of bile acids, preventing their build-up and reducing fat accumulation.
- Reducing Liver inflammation: By mitigating oxidative stress and supporting detoxification pathways, CureDiab’s compounds help calm chronic inflammation within the liver.
- Modulating gut Microbiota: Emerging research indicates a link between gut health and NAFLD. Sulfur compounds can positively influence the gut microbiome, promoting a healthier balance of bacteria.
Clinical Trial Data and Early Results
Initial Phase II clinical trials, completed in late 2025, showed promising results. Participants with biopsy-confirmed NASH experienced:
* Significant reduction in liver fat content: Measured via MRI.
* Improved liver enzyme levels (ALT & AST): Indicating reduced liver damage.
* Decreased markers of inflammation: Suggesting a reduction in NASH activity.
* No significant adverse side effects: Demonstrating a favorable safety profile.
While larger Phase III trials are currently underway, these early findings have generated considerable excitement within the gastroenterology and hepatology communities. The data suggests a potential disease-modifying effect, rather than simply managing symptoms.
The Growing Prevalence of Fatty Liver Disease
NAFLD is rapidly becoming one of the most common chronic liver diseases globally, closely linked to the rising rates of obesity, type 2 diabetes, and metabolic syndrome.It’s often a “silent” disease, meaning many individuals are unaware they have it until significant liver damage has occurred.
Risk Factors for NAFLD/NASH:
* Obesity
* Type 2 Diabetes
* High Cholesterol & Triglycerides
* Metabolic Syndrome
* Poor Diet (high in processed foods, sugar, and saturated fats)
* Sedentary Lifestyle
Beyond Treatment: Preventative strategies & Lifestyle Modifications
While CureDiab’s compounds offer a targeted therapeutic approach, preventative measures remain crucial.Adopting a liver-kind lifestyle can significantly reduce your risk of developing NAFLD/NASH:
* Diet: Focus on a Mediterranean-style diet rich in fruits, vegetables, whole grains, and healthy fats. Limit processed foods,sugary drinks,and excessive alcohol consumption.
* Exercise: Regular physical activity helps improve insulin sensitivity and reduce liver fat. Aim for at least 150 minutes of moderate-intensity exercise per week.
* Weight Management: Even modest weight loss can have a significant impact on liver health.
* Regular Check-ups: If you have risk factors for NAFLD, discuss screening with your doctor.
The Future of Liver Health: CureDiab’s Vision
curediab’s commitment extends beyond developing pharmaceutical interventions. The company is also investing in diagnostic tools to improve early detection of NAFLD and personalized treatment strategies based on individual metabolic profiles. Their long-term vision is to shift the paradigm of liver disease management from reactive treatment to proactive prevention and targeted metabolic correction. The company anticipates seeking regulatory approval for its lead compound in key markets by late 2027.
